Epoetin alfa as a supportive measure in hematologic malignancies

Seminars in Hematology

Volumn 39, Issue 4 SUPPL. 3, 2002, Pages 25-31

  Straus, David J ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOKINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GROWTH FACTOR; PLACEBO; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; BLOOD TRANSFUSION; BONE MARROW SUPPRESSION; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE SEVERITY; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG TOLERABILITY; HEMATOLOGIC MALIGNANCY; HODGKIN DISEASE; HUMAN; MULTIPLE MYELOMA; MUSCLE WEAKNESS; MYELODYSPLASTIC SYNDROME; PATHOGENESIS; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SIDE EFFECT; TREATMENT OUTCOME;

EID: 0036814463     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1053/shem.2002.36926     Document Type: Article

References (21)

1. Groopman JE, Itri LM: Chemotherapy-induced anemia in adults: Incidence and treatment. J Natl Cancer Inst 91:1616-1633, 1999
2. Littlewood TJ: Erythropoietin for the treatment of anemia associated with hematological malignancy. Hematol Oncol 19:19-30, 2001
3. Coiffier B: Anemia associated with non-platinum chemotherapy (CT) for Hodgkin's lymphoma (HL) or non-Hodgkin's lymphoma (NHL). Eur J Cancer 35:S331, 1999 (suppl 4, abstr 1331)
4. Curt GA: Fatigue in cancer. BMJ 322:1560, 2001 (editorial)
5. Miller CB, Jones RJ, Piantadosi S, et al: Decreased erythropoietin response in patients with the anemia of cancer. N Engl J Med 322:1689-1692, 1990
6. Gabrilove JL: New strategies and treatment modalities for optimizing patient outcomes. Semin Hematol 38:1-7, 2001 (suppl 7)
7. Ludwig H, Frittz E, Kotzmann H, et al: Erythropoietin treatment of anemia associated with multiple myeloma. N Engl J Med 322:1693-1699, 1990
8. Österborg A, Boogaerts MA, Cimino R, et al: Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin's lymphoma - A randomized multicenter study. Blood 87:2675-2682, 1996
9. Littlewood TJ, Bajetta E, Nortier JWR, et al: Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: Results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 19:2865-2874, 2001
10. Glaspy J, Bukowski R, Steinberg D, et al: Impact of therapy with epoetin alfa on clinical outcomes in patients with non-myeloid malignancies during cancer chemotherapy in community oncology practice. J Clin Oncol 15:1218-1234, 1997
11. Demetri GD, Kris M, Wade J, et al: Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: Results from a prospective community oncology study. J Clin Oncol 16:3412-3425, 1998
12. Gabrilove JL, Cleeland CS, Livingston RB, et al: Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: Improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 19:2875-2882, 2001
13. Casadevall N: Update on the role of epoetin alfa in hematologic malignancies and myelodysplastic syndromes. Semin Oncol 25:12-18, 1998 (suppl 7)
14. Rose EH, Abels RI, Nelson RA, et al: The use of r-HuEpo in the treatment of anaemia related to myelodysplasia (MDS). Br J Haematol 89:831-837, 1995
15. Thompson JA, Gilliland DG, Prchal JT, et al: Effect of recombinant human erythropoietin combined with granulocyte/macrophage colony-stimulating factor in the treatment of patients with myelodysplastic syndrome. Blood 95:1175-1179, 2000
16. Negrin RS, Stein R, Doherty K, et al: Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor and erythropoietin: Evidence for in vivo synergy. Blood 87:4076-4081, 1996
17. Rose E, Rai K, Revicki D, et al: Clinical and health status assessments in anemic chronic lymphocytic leukemia (CLL) patients treated with epoetin alfa (EPO). Blood 84:526a, 1994 (suppl 1, abstr 2091)
18. Cazzola M, Messinger D, Battistel V, et al: Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin's lymphoma: Dose finding and identification of predictors of response. Blood 86:4446-4453, 1995
19. Dammacco F, Castoldi G, Rodjer S: Efficacy of epoetin alfa in the treatment of anaemia of multiple myeloma. Br J Haematol 113:172-179, 2001
20. Crawford J, Cella D, Cleeland CS, et al: Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer 95:888-895, 2002
21. Cella D and Webster KA: Quality of life and treatment value in the management of hematologic malignancies. Semin Oncol 26:34-42, 1999 (suppl 14)